Skip to main content

Table 3 Comparison of clinical manifestations and laboratory tests with different EVs infected patients

From: Co-circulation of coxsackieviruses A-6, A-10, and A-16 causes hand, foot, and mouth disease in Guangzhou city, China

 

Total

CVA-6

CVA-10

CVA-16

Clinical symptoms and signs

Total patients

N = 1220

N = 364

N = 305

N = 397

 Cough

304(24.9%)

101(27.7%)

65(21.3%)

96(24.2%)

 Diarrhea

60(4.9%)

14(3.8%)

14(4.6%)

22(5.5%)

 Vomiting

228(18.7%)

60(16.5%)

67(22.0%)

79(19.9%)

 Fever spike (°C)

39.3(39.0–39.8)

39.4(39.0–39.8)

39.5(39.0–39.9)

39.0(38.9–39.9)

 Fever (> 38 °C)

1093(89.6%)

327(89.8%)

280(91.8%)

360(90.7%)

 Neurologic complications

61(5.0%)

20(5.5%)

16(5.2%)

6(1.5%)*

 Skin lesion

1220(100%)

364(100%)

305(100%)

397(100%)

 Mouth and/or pharyngeal

1056(86.6%)

300(82.4%)

270(88.5%)

340(85.7%)

 Hands and /or feet

1117(91.6%)

339(93.1%)

264(86.6%)

354(89.2%)

 Trunk

210(17.2%)

76(20.9%)

51(16.7%)

72(18.1%)

 Extremities

1115(91.4%)

342(94.0%)

267(87.5%)

362(91.2%)

Laboratory data

Total patients

N = 1220

N = 364

N = 305

N = 397

 hsCRP(0-10 mg/L)

6.93(2.50–17.08)

9.67(3.68–22.84)

14.26(3.92–27.3)

4.23(2.50–8.90)*

 hsCRP (> 2.5 mg/L)

868(71.1%)

293(80.5%)*

236(77.4%)

246(62.0%)

 WBC(5-12 × 109/L)

9.9(7.8–12.6)

9.3(7.1–12.5)

11.9(8.9–14.6)*

9.48(7.8–11.3)

 WBC > 12 × 109/L

362(29.7%)

110(30.2%)

146(47.9%)*

74(18.6%)

 Neutrophils (3-10 × 109/L)

5.3(3.4–8.0)

4.3(2.7–8.1)

7.1(4.5–10.1)*

4.9(3.7–6.5)

 Neutrophils(> 10 × 109/L)

167(13.7%)

53(14.6%)

80(26.2%)*

20(5.0%)

 Lymphocyte (1.1–3.2 × 109/L)

3.1(2.3–4.1)

3.2(2.4–4.3)

3.0(2.2–3.9)

3.2(2.4–4.2)

 Lymphocyte(> 3.2 × 109/L)

563(46.1%)

197(49.2%)

126(41.3%)

196(49.4%)

  PLT (150-400 × 109/L)

274(231–329)

274(232–334)

273(229–339)

278(227–324)

 PLT(> 400 × 109/L)

109(8.9%)

30(8.2%)

26(8.5%)

36(9.1%)

Total patients

N = 758

N = 236

N = 204

N = 246

 AST (30-40 U/L)

36(31–41)

35(30–41)

36(32–40)

36(31–41)

 AST(> 40 U/L)

183(24.1%)

60(25.4%)

45(22.1%)

66(26.8%)

 CK (30-135 U/L)

94(72–118)

90(69–111)

96(75–120)

97(72–126)

 CK(> 135 U/L)

126(16.6%)

50(21.2%)

36(17.6%)

34(13.8%)

 CK-MB(0-25 U/L)

20(16–25)

21(16–25)

19(15–24)

22(16–25)

 CK-MB(> 25 U/L)

169(22.3%)

52(22.0%)

43(21.1%)

60(24.4%)

  1. Continuous data are presented as median (interquartile range) and categorical data are presented as n (%)
  2. * Significant different compare with other groups, P < 0.05
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us